Drug Development

Articles

Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.

Crystec, Biosidus Collaborate on Enhanced Delivery and Performance of Biotherapeutics 

EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.

EMA Approves Two New Manufacturing Sites and a New Formulation for Comirnaty

EMA has started its evaluation of further expanded use of Comirnaty in children aged between five years and 11 years old.

EMA Starts Evaluation of Comirnaty in Children

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery. 

Considerations for DPIs and MDIs in Inhalation Drug Delivery

AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.

AstraZeneca’s AZD7442 Clinical Trial Meets Primary Endpoint

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Reformulation strategies are useful tools for more than just stretching out the potential return on investment for a product.

Considering Bio/Pharma Reformulation Strategies

Novartis and Medicines for Malaria Venture have reported positive results from the Phase IIb study, evaluating a new non-artemisinin combination to treat uncomplicated malaria in children.

Novartis and MMV Report Positive Results for Next-Generation Antimalarial Therapy

Meg Rivers is the former senior editor for 

Alternatives to animal testing and in-vivo assays are occurring as a result of recent scientific advances.

In Vivo Falls Behind In Vitro for Adventitious Agent Testing

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Biosimilar approvals and the advance of biosimilar testing and production may lead to greater access to alternative therapies.

Formulation and Drug Delivery